Share This Article:

MicroRNA-22E Inhibits HER-3 Protein Expression to Facilitate Metastasis of Lung Adenocarcinomas

Abstract Full-Text HTML XML Download Download as PDF (Size:4792KB) PP. 362-374
DOI: 10.4236/jct.2015.64039    2,527 Downloads   2,868 Views  

ABSTRACT

MicroRNA-22 (miR-22), a short non-coding RNA that post-transcriptionally regulates mRNA stability and protein synthesis, has been shown to enhance metastatic potential and to suppress HER-3, an important mRNA marker for non-small cell lung cancer (NSCLC). However, the effect of miR-22 has not been investigated in lung adenocarcinoma (LADC), the most common type of NSCLC in the Far East. In this study, we analyzed the role of miR-22 expression in LADC patients. Expression of miR-22 was detected by reverse-transcription polymerase chain reaction (RT-PCR), and confirmed by cDNA sequencing. Signals of miR-22 in LADC sections were identified using in situ hybridization (ISH). The association between miR-22 expression and survival was evaluated by the log-rank test. Induction of miR-22 expression and the effect on HER-3 levels, as well as the subsequent cell behavior were also investigated In vitro. Two types of miR-22: miR-22 and miR-22H, were detected by RT-PCR. The miR-22H had extra 13 bases, 5’-TGTGTTCAGTGGT-3’, at the 3’-end, and this segment was named miR-22E. Using ISH, miR-22E overexpression was detected in 225 (83.0%) of 271 LADC patients. A significant difference was found in cumulative survival between patients with high miR-22E levels and those with low miR-22E levels (p < 0.0001). In vitro, epidermal growth factor induced miR-22, but reduced HER-3 expression. Expression of miR-22 increased cell movement ability. In conclusion, expression of miR-22 is closely associated with tumor recurrence, metastasis and overall survival in LADC patients by suppressing HER-3 protein expression to enhance epithelial-mesenchymal transition and metastasis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Fang, H. , Lin, T. , Chiou, S. , Wang, L. and Chow, K. (2015) MicroRNA-22E Inhibits HER-3 Protein Expression to Facilitate Metastasis of Lung Adenocarcinomas. Journal of Cancer Therapy, 6, 362-374. doi: 10.4236/jct.2015.64039.

References

[1] Huang, S.-F., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H.-Y., et al. (2004) High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non-Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan. Clinical Cancer Research, 10, 8195-8203.
http://dx.doi.org/10.1158/1078-0432.CCR-04-1245
[2] Wu, J.-Y., Wu, S.-G., Yang, C.-H., Chang, Y.-L., Chang, Y.-C., Hsu, Y.-C., et al. (2011) Comparison of Gefitinib and Erlotinib in Advanced NSCLC and the Effect of EGFR Mutations. Lung Cancer, 72, 205-212.
http://dx.doi.org/10.1016/j.lungcan.2010.08.013
[3] Chen, J.-T., Lin, T.-S., Chow, K.-C., Huang, H.-H., Chiou, S.-H., Chiang, S.-F., et al. (2006) Cigarette Smoking Induces Overexpression of Hepatocyte Growth Factor in Type II Pneumocytes and Lung Cancer cells. American Journal of Respiratory Cell and Molecular Biology, 34, 264-273.
http://dx.doi.org/10.1165/rcmb.2005-0117OC
[4] Chen, J.-T., Huang, C.-Y., Chiang, Y.-Y., Chen, W.-H., Chiou, S.-H., Chen, C.-Y., et al. (2008) HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells. American Journal of Respiratory Cell and Molecular Biology, 38,559-565.
http://dx.doi.org/10.1165/rcmb.2007-0001OC
[5] Hsu, N.Y., Ho, H.C., Chow, K.C., Lin, T.-Y., Shih, C.-S., Wang, L.-S., et al. (2001) Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker of Non-Small Cell Lung Cancer. Cancer Research, 61, 2727-2731.
[6] Chiang, Y.-Y., Chen, S.-L., Hsiao, Y.-T., Huang, C.-H., Lin, T.-Y., Chiang, I.-P., et al. (2009) Nuclear Expression of Dynamin-Related Protein 1 in Lung Adenocarcinomas. Modern Pathology, 22, 1139-1150.
http://dx.doi.org/10.1038/modpathol.2009.83
[7] Fang, H.Y., Chang, C.L., Hsu, S.H., Huang, C.Y., Chiang, S.F., Chiou, S.H., et al. (2010) ATPase Family AAA Domain-Containing 3A Is a Novel Anti-Apoptotic Factor in Lung Adenocarcinoma Cells. Journal of Cell Science, 123, 1171-1180.
[8] You, W.-C., Chiou, S.-H., Huang, C.-Y., Chiang, S.-F., Yang, C.-L., Sudhakar, J.N., et al. (2013) Mitochondrial Protein ATPase Family, AAA Domain Containing 3A Correlates with Radioresistance in Glioblastoma. Neuro-Oncology, 15, 1342-1352.
http://dx.doi.org/10.1093/neuonc/not077
[9] Chen, D.-R., Chu, C.-Y., Chen, C.-Y., Yang, H.-C., Chiang, Y.-Y., Lin, T.-Y., et al. (2008) Expression of Short Form Oncostatin M Receptor as a Decoy Receptor in Lung Adenocarcinomas. The Journal of Pathology, 215, 290-299.
http://dx.doi.org/10.1002/path.2361
[10] Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., et al. (2007) A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 356, 11-20.
http://dx.doi.org/10.1056/NEJMoa060096
[11] Olayioye, M.A., Neve, R.M., Lane, H.A. and Hynes, N.E. (2000) The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer. The EMBO Journal, 19, 3159-3167.
http://dx.doi.org/10.1093/emboj/19.13.3159
[12] Sierke, S.L., Cheng, K., Kim, H.H. and Koland, J.G. (1997) Biochemical Characterization of the Protein Tyrosine kinase Homology Domain of the ErbB3 (HER3) Receptor Protein. Biochemical Journal, 322, 757-763.
[13] Steinberg, F., Zhuang, L., Beyeler, M., Kalin, R.E., Mullis, P.E., Brandli, A.W., et al. (2010) The FGFRL1 Receptor Is Shed from Cell Membranes, Binds Fibroblast Growth Factors (FGFs), and Antagonizes FGF Signaling in Xenopus Embryos. The Journal of Biological Chemistry, 285, 2193-2202.
http://dx.doi.org/10.1074/jbc.M109.058248
[14] Bogdan, S. and Klambt, C. (2001) Epidermal Growth Factor Receptor Signaling. Current Biology, 11, R292-R295.
http://dx.doi.org/10.1016/S0960-9822(01)00167-1
[15] Hellyer, N.J., Cheng, K. and Koland, J.G. (1998) ErbB3 (HER3) Interaction with the p85 Regulatory Subunit of Phosphoinositide 3-Kinase. Biochemical Journal, 333, 757-763.
[16] Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233.
http://dx.doi.org/10.1016/j.cell.2009.01.002
[17] Patel, J.B., Appaiah, H.N., Burnett, R.M., Bhat-Nakshatri, P., Wang, G., Mehta, R., et al. (2011) Control of EVI-1 Oncogene Expression in Metastatic Breast Cancer Cells through microRNA miR-22. Oncogene, 30, 1290-1301.
http://dx.doi.org/10.1038/onc.2010.510
[18] Larue, L. and Bellacosa, A. (2005) Epithelial-Mesenchymal Transition in Development and Cancer: Role of Phosphatidylinositol 3’Kinase/AKT Pathways. Oncogene, 24, 7443-7454.
http://dx.doi.org/10.1038/sj.onc.1209091
[19] Bar, N. and Dikstein, R. (2010) miR-22 Forms a Regulatory Loop in PTEN/AKT Pathway and Modulates Signaling Kinetics. PLoS One, 5, e10859.
http://dx.doi.org/10.1371/journal.pone.0010859
[20] Kasahara, K., Arao, T., Sakai, K., Matsumoto, K., Sakai, A., Kimura, H., et al. (2010) Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma. Clin Cancer Res, 16, 4616-4624.
http://dx.doi.org/10.1158/1078-0432.CCR-10-0383
[21] Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., et al. (2008) Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Research, 68, 9479-9487.
http://dx.doi.org/10.1158/0008-5472.CAN-08-1643
[22] Mountain, C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-1717.
http://dx.doi.org/10.1378/chest.111.6.1710
[23] Kaplan, E.L. and Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481.
http://dx.doi.org/10.1080/01621459.1958.10501452
[24] Mantel, N. (1966) Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration. Cancer Chemotherapy Reports, 50, 163-170.
[25] Chen, C.-Y., Fang, H.-Y., Chiou, S.-H., Yi, S.-E., Huang, C.-Y., Chiang, S.-F., et al. (2011) Sumoylation of Eukaryotic Elongation Factor 2 Is Vital for Protein Stability and Anti-Apoptotic Activity in Lung Adenocarcinoma Cells. Cancer Science, 102, 1582-1589.
http://dx.doi.org/10.1111/j.1349-7006.2011.01975.x
[26] Lee, Y., Jeon, K., Lee, J.T., Kim, S. and Kim, V.N. (2002) MicroRNA Maturation: Stepwise Processing and Subcellular Localization. The EMBO Journal, 21, 4663-4670.
http://dx.doi.org/10.1093/emboj/cdf476
[27] Flynt, A.S., Greimann, J.C., Chung, W.J., Lima, C.D. and Lai, E.C. (2010) MicroRNA Biogenesis via Splicing and Exosome-Mediated Trimming in Drosophila. Molecular Cell, 38, 900-907.
http://dx.doi.org/10.1016/j.molcel.2010.06.014
[28] Song, S.J., Poliseno, L., Song, M.S., Ala, U., Webster, K., Ng, C., et al. (2013) MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 154, 311-324.
http://dx.doi.org/10.1016/j.cell.2013.06.026
[29] Kong, D.J., Li, Y.W., Wang, Z.W., Banerjee, S., Ahmad, A., Choi Kim, H.-R. and Sarkar, F.H. (2009) miR-200 Regulates PDGF-D-Mediated Epithelial-Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells. Stem Cells, 27, 1712-1721.
http://dx.doi.org/10.1002/stem.101
[30] Pecot, C.V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C.H., et al. (2013) Tumour Angiogenesis Regulation by the miR-200 Family. Nature Communications, 4, Article Number: 2427.
http://dx.doi.org/10.1038/ncomms3427
[31] Park, S.M., Gaur, A.B., Lengyel, E. and Peter, M.E. (2008) The miR-200 Family Determines the Epithelial Phenotype of Cancer Cells by Targeting the E-Cadherin Repressors ZEB1 and ZEB2. Genes & Development, 22, 894-907.
http://dx.doi.org/10.1101/gad.1640608
[32] Korpal, M., Ell, B.J., Buffa, F.M., Ibrahim, T., Blanco, M.A., Celià-Terrassa, T., et al. (2011) Direct Targeting of Sec23a by miR-200s Influences Cancer Cell Secretome and Promotes Metastatic Colonization. Nature Medicine, 17, 1101-1108.
http://dx.doi.org/10.1038/nm.2401
[33] Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4, 988-1004.
http://dx.doi.org/10.1038/nrd1902
[34] Shen, J., Xia, W.Y., Khotskaya, Y.B., Huo, L.F., Nakanishi, K., Lim, S.-O., et al. (2013) EGFR Modulates microRNA Maturation in Response to Hypoxia through Phosphorylation of AGO2. Nature, 497, 383-387.
http://dx.doi.org/10.1038/nature12080
[35] Jin, K., Mao, X.O., Sun, Y., Xie, L., Jin, L., Nishi, E., et al. (2002) Heparin-Binding Epidermal Growth Factor-Like Growth Factor: Hypoxia-Inducible Expression in Vitro and Stimulation of Neurogenesis in Vitro and in Vivo. The Journal of Neuroscience, 22, 5365-5373.
[36] Minakata, K., Takahashi, F., Nara, T., Hashimoto, M., Tajima, K., Murakami, A., et al. (2012) Hypoxia Induces Gefitinib Resistance in Non-Small-Cell Lung Cancer with Both Mutant and Wild-Type Epidermal Growth Factor Receptors. Cancer Science, 103, 1946-1954.
http://dx.doi.org/10.1111/j.1349-7006.2012.02408.x
[37] Tavaluc, R.T., Hart, L.S., Dicker, D.T. and El-Deiry, W.S. (2007) Effects of Low Confluency, Serum Starvation and Hypoxia on the Side Population of Cancer Cell Lines. Cell Cycle, 6, 2554-2562.
http://dx.doi.org/10.4161/cc.6.20.4911
[38] Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., et al. (2006) Unique MicroRNA Molecular Profiles in Lung Cancer Diagnosis and Prognosis. Cancer Cell, 9, 189-198.
http://dx.doi.org/10.1016/j.ccr.2006.01.025
[39] Chiang, Y.Y., Chow, K.C., Lin, T.Y., Chiang, I.P. and Fang, H.Y. (2014) Hepatocyte Growth Factor and HER2/Neu Downregulate Expression of Apoptosis-Inducing Factor in Non-Small Cell Lung Cancer. Oncology Reports, 31, 597-604.
[40] Lowery, A.J., Miller, N., Devaney, A., McNeill, R.E., Davoren, P.A., Lemetre, C., et al. (2009) MicroRNA Signatures Predict Oestrogen Receptor, Progesterone Receptor and HER2/Neureceptor Status in Breast Cancer. Breast Cancer Research, 11, R27.
http://dx.doi.org/10.1186/bcr2257

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.